ImmunityBio, Inc. clinical trial failures

Review 39 stopped clinical trials from ImmunityBio, Inc., including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 5 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials39

Likely biological signals5

Shown below39

Dominant stop reasons

OPERATIONAL: 22
OTHER/UNKNOWN: 12
SAFETY: 5

Notable sponsors

ImmunityBio, Inc.: 39

Related phases

Phase I: 26
Phase II: 9
Phase III: 4

Crawlable stopped-trial records

Open Explore

Showing up to 39 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT07524257: Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

Phase III NSCLC (Advanced Non-small Cell Lung Cancer) trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Sponsor decision

NCT03520686: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase III Non Small Cell Lung Cancer trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.

NCT07551544: ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Phase III NMIBC trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Sponsor decision

NCT07492888: Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

Phase II Acute Respiratory Distress Syndrome trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

New protocol developed

NCT07492875: Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Phase III Community-Acquired Pneumonia (CAP) trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

New protocol developed

NCT06765902: Immunotherapy Before and After Surgery

Phase II High-risk Prostate Cancer trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Study was redeveloped into a new protocol

NCT06765954: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Phase II High-risk Prostate Cancer trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Study was redeveloped into a new protocol

NCT05370040: THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Phase I COVID-19 trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Discontinued prior to enroll in Phase 2

NCT03169790: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase I Non Hodgkin Lymphoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03169764: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase I Head and Neck Squamous Cell Carcinoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03167177: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase I Melanoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT04052061: QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

Phase I Diffuse Large B Cell Lymphoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03563144: QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase II Metastatic Pancreatic Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03167164: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase I Merkel Cell Carcinoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03647423: QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Phase I Chordoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03197571: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase I Urothelial Carcinoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT04845191: COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Phase I Covid19 trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

The sponsor has changed the development plans which is not for safety reasons.

NCT04843722: COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Phase I Covid19 trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

The sponsor has changed the development plans which is not for safety reasons.

NCT03197584: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase I Ovarian Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03574649: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase II Non Small Cell Lung Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03169777: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase I Colorectal Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03175666: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase I Triple Negative Breast Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03554109: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Phase II Triple Negative Breast Cancer (TNBC) trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03169738: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase I Non-small Cell Lung Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Trial not initiated

NCT03329248: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase I Pancreatic Cancer trial by ImmunityBio, Inc.. Stop reason: SAFETY.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Phase I Colorectal Cancer Metastatic trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

low enrollment

NCT04732468: COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Phase I Covid19 trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

The study was terminated early due to low enrollment.

NCT04397796: Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

Phase I COVID trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

NCT04385849: Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Phase I COVID-19 trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

NCT03586869: QUILT-3.080: NANT Pancreatic Cancer Vaccine

Phase I Pancreatic Cancer trial by ImmunityBio, Inc.. Stop reason: SAFETY.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT03387085: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase I Triple Negative Breast Cancer trial by ImmunityBio, Inc.. Stop reason: SAFETY.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT03853317: QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Phase II Merkel Cell Carcinoma trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Not meeting recruitment goal

NCT03387111: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Phase I Squamous Cell Carcinoma trial by ImmunityBio, Inc.. Stop reason: SAFETY.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT04927884: A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase I Advanced Triple Negative Breast Cancer trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

low enrollment

NCT03136406: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase I Pancreatic Cancer trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT06022224: A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Phase II COVID-19 trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.

NCT03387098: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase I Pancreatic Cancer trial by ImmunityBio, Inc.. Stop reason: SAFETY.

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

NCT02465957: QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

Phase II Stage IIIB Merkel Cell Carcinoma trial by ImmunityBio, Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT03563170: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Phase I Hepatocellular Carcinoma Non-resectable trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.

Enrollment not initiated